Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a corporate governance notification regarding share capital.
Material Changes
The filing details the Company's issued share capital as of April 28, 2017:
- Total issued ordinary shares: 5,370,638,397 (25 pence each).
- Shares held in Treasury: 453,205,950.
- Total voting rights: 4,917,432,447.
No material changes to financial operations or strategic direction are reported in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to provide the denominator for shareholders to calculate notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,917,432,447) against the latest annual report (Form 20-F) to confirm consistency.
- Confirm the number of shares held in Treasury (453,205,950) to assess potential buyback activity or share issuance plans.
- Check subsequent filings for any changes to the share capital structure following the April 28, 2017 date.